Dr Timothy Yap talks to ecancer in an online interview about the KEYNOTE-158 trial, a phase 2 global, open-label, single-arm, multicohort study that evaluates pembrolizumab in several rare advanced solid tumour types including mesothelioma.

He describes the preliminary data that supports the use of pembrolizumab in advanced mesothelioma before outlining the trial design of KEYNOTE-158.

Dr Yap goes on to discuss the possibility of combinations with pembrolizumab also being explored in this setting.

This programme has been supported by an unrestricted educational grant from Bristol Myers Squibb.